DLPFC transcriptome defines two molecular subtypes of schizophrenia

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• The molecular pathogenesis of schizophrenia remains poorly understood, potentially due to unrecognized patient population heterogeneity.
• Previous research has faced challenges in identifying consistent molecular markers across all diagnosed individuals.

Purpose of the Study:

• To investigate gene expression differences in the dorsolateral prefrontal cortex (DLPFC) to identify potential molecular subtypes of schizophrenia.
• To explore the biological basis of heterogeneity within diagnosed schizophrenia patient cohorts.

Main Methods:

• Analysis of gene expression data from post-mortem dorsolateral prefrontal cortex (DLPFC) samples of schizophrenia patients and matched controls.
• Utilized Bonferroni correction for statistical significance and Weighted Gene Co-expression Network Analysis (WGCNA).
• Replicated findings in an independent cohort using RNA sequencing data.

Main Results:

• Identified 633 differentially expressed genes in the DLPFC of schizophrenic patients compared to controls.
• Weighted Gene Co-expression Network Analysis (WGCNA) divided schizophrenic subjects into two distinct groups based on gene expression patterns.
• "Type 1" schizophrenia showed minimal gene expression changes (4 genes), while "Type 2" exhibited significant transcriptomic alterations (3092 genes), replicated across cohorts.

Conclusions:

• The study provides strong evidence for at least two distinct biological subtypes of schizophrenia based on DLPFC transcriptomic profiles.
• These findings suggest a fundamental biological difference between "Type 1" and "Type 2" schizophrenia, necessitating tailored research and treatment approaches.
• Further research is warranted to validate and expand upon these distinct molecular subtypes.